Pharvaris (NASDAQ:PHVS - Get Free Report)'s share price gapped down before the market opened on Monday . The stock had previously closed at $16.67, but opened at $16.23. Pharvaris shares last traded at $16.77, with a volume of 4,984 shares trading hands.
Analyst Upgrades and Downgrades
Separately, JMP Securities raised their price objective on Pharvaris from $46.00 to $55.00 and gave the stock a "market outperform" rating in a research note on Friday, January 31st.
View Our Latest Research Report on Pharvaris
Pharvaris Trading Down 0.4 %
The firm has a 50-day simple moving average of $16.92 and a two-hundred day simple moving average of $19.06. The company has a market capitalization of $805.27 million, a price-to-earnings ratio of -5.50 and a beta of -3.02.
Institutional Inflows and Outflows
Institutional investors have recently bought and sold shares of the stock. Public Employees Retirement System of Ohio acquired a new stake in shares of Pharvaris during the 3rd quarter worth approximately $57,000. JPMorgan Chase & Co. boosted its holdings in Pharvaris by 1,125.3% in the 4th quarter. JPMorgan Chase & Co. now owns 3,100 shares of the company's stock worth $59,000 after buying an additional 2,847 shares during the last quarter. Cubist Systematic Strategies LLC acquired a new position in shares of Pharvaris during the fourth quarter valued at approximately $64,000. Barclays PLC purchased a new position in shares of Pharvaris in the third quarter valued at approximately $106,000. Finally, KLP Kapitalforvaltning AS acquired a new stake in shares of Pharvaris in the fourth quarter worth approximately $111,000.
About Pharvaris
(
Get Free Report)
Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial.
Further Reading
Before you consider Pharvaris, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pharvaris wasn't on the list.
While Pharvaris currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Get this report to learn how options trading can help you use the market’s volatility to your advantage.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
